Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1906)	9/28/2007 12:48:33 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CBTE Wants to go up without closing its Sep 18 UG.<g> It commented today on its recent acquisitions,"successful initiatives" & "Quarter Highlights" biz.yahoo.com The stock was up 10.66% on low volume of 29,300 (but still almost 3x its ADV <g>) bigcharts.marketwatch.com The stock needs to close above $3.30 in order to get off from the DT coming from its June H of 3.99 bigcharts.marketwatch.com It has reported better revenues in the last 2Qs,specially on the June Q, but hasn't been able to trim its losses.The insiders hold > 50% The Feb 200 H was 30 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1906)	1/26/2008 12:45:34 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ALSE, the former Boston Life Sciences, was up 11.7% on very small volume of only 600 shrs., about 0.001 of its ADV. The stock is getting close to its resistance at the $3 level bigcharts.marketwatch.com ALSE is trying to develop drugs to treat injuries and degenerative diseases & has intellectual property in the field of regenerative therapeutics. Its Cethrin, is a recombinant-protein-based drug designed to stimulate nerve repair after acute spinal cord injury. In its PIa, it showed some positive results.On Jan 7, it announced that it has concluded enrollment in the PI/IIa for acute spinal cord injury. ALSE also has in its pipeline Inosine for the treatment of spinal cord injury & stroke; Oncomodulin for the treatment of ocular injury & disease, & some research programs for a number of regenerative therapies including bone repair. It also has a molecular imaging program targeting diagnosis of Parkinson's & ADHD. Its molecular imaging product candidate is ALTROPANE, which is in PIII for diagnosis of Parkinson's Disease. It has research collaborations with Harvard & Boston's Children's Hospital. The stock needs to close above $3 in order to get off from the DT coming from its June H at 3.52 bigcharts.marketwatch.com. And then it would have to deal with the Aug-Sep 2006 double top at the 4.24 level Bernard